Companies · Biotechnology

Bio-Dent, LTD. LLC

SIMI VALLEY · Biotechnology

Diligence memoA one-page analyst read on Bio-Dent, LTD. LLC — recommendation, valuation, rhythm, risks.→
$15.0M
Total raised · real
1
Rounds
—
Latest step-up
Top 38%
Sector rank · raised
Series A
Latest stage · inferred · Sat Jul 01 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Bio-Dent, LTD. LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.57× the median modeled value of Series A Biotechnology companies in 2016–2018 (157 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 9.0 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Bio-Dent, LTD. LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
9.3 yr record
Peak capital year was 2017 with $15.0M across 1 filings.
Market position
ahead of 63% of Biotechnology peers
Capital scale is ahead of 63% of Biotechnology peers; modeled value is above 84% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $15.0M across 1 filings.
  • Largest single filing was $15.0M on 2017-07-01.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Bio-Dent, LTD. LLC is one of 4293 Biotechnology companies tracked from SIMI VALLEY. By capital raised it ranks mid-pack (ahead of 63% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2015
Year incorporated
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2017-07-01 Raised $15M (real) Modeled valuation $542M (est)$15M$542MSeries A2017

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$15.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 33%.

Modeled valuation trajectory
$542.3M
Base estimate est.
$16.4M
Conservative case
$2.9B
Upside case
$68.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series A — a $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
9.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
—
Avg between rounds
—
Capital velocity
9.3 yr
On record since
2017
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)▲ 2.1× above median
This company$15.0M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage)▲ 2.8× above median
This company$15.0M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages)▲ 8.5× above median
This company$542.3M
Sector median$64.2M

Raised more than 63% of sector peers (real $). Modeled value above 84% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 157.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Anthera Pharmaceuticals Inc · Series A Raised $15.0M · modeled $542.3M (est)Cynvec LLC · Series A Raised $17.4M · modeled $542.3M (est)Biothera Holding Corp. · Series A Raised $16.2M · modeled $529.3M (est)Limelight Bio, Inc. · Series A Raised $14.0M · modeled $506.2M (est)Overture Life, Inc. · Series A Raised $13.6M · modeled $491.7M (est)TAI Diagnostics, Inc. · Series A Raised $21.1M · modeled $463.8M (est)Occulo Holdings LLC · Series A Raised $12.8M · modeled $462.7M (est)Agilis Biotherapeutics, Inc. · Series A Raised $25.7M · modeled $458.0M (est)CAMBRIDGE EPIGENETIX Ltd · Series A Raised $12.3M · modeled $444.4M (est)Genten Therapeutics, Inc. · Series A Raised $12.0M · modeled $433.8M (est)LTC BioSciences, Inc · Series A Raised $12.0M · modeled $433.8M (est)Bio-Dent, LTD. LLC (this company) Raised $15.0M · modeled $542.3M (est)Bio-Dent, LTD. LLC
CompanyStageRaised · realValue · estvs peer med.
Bio-Dent, LTD. LLC this companySeries A$15.0M$542.3M2.57×
Anthera Pharmaceuticals IncSeries A$15.0M$542.3M2.57×
Cynvec LLCSeries A$17.4M$542.3M2.57×
Biothera Holding Corp.Series A$16.2M$529.3M2.51×
Limelight Bio, Inc.Series A$14.0M$506.2M2.40×
Overture Life, Inc.Series A$13.6M$491.7M2.33×
TAI Diagnostics, Inc.Series A$21.1M$463.8M2.20×
Occulo Holdings LLCSeries A$12.8M$462.7M2.19×
Agilis Biotherapeutics, Inc.Series A$25.7M$458.0M2.17×
CAMBRIDGE EPIGENETIX LtdSeries A$12.3M$444.4M2.11×
Genten Therapeutics, Inc.Series A$12.0M$433.8M2.06×
LTC BioSciences, IncSeries A$12.0M$433.8M2.06×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$15.0M2017-07-01$68.2M$542.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$15.0M2017-07-01
    • First recorded raise — entered as Series A.
Intelligence
—
Modeled next raise
$24.0M
Modeled next size est.range $15.6M–$38.4M
—
Last step-up
—
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Rami Rostami——2017-07
Sargon Lazarof——2017-07
Registry & provenance

Bio-Dent, LTD. LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1706292
SEC CIK
2015
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Anthera Pharmaceuticals IncBiotechnologySeries A$15.0M$542.3Msame sector · same stage
Genethera IncBiotechnologySeries A$15.0M$355.1Msame sector · same stage
Nexus Dx, Inc.BiotechnologySeries A$15.0M$325.4Msame sector · same stage
TechAccel, LLCBiotechnologySeries A$15.0M$542.3Msame sector · same stage
TRACT Therapeutics, Inc.BiotechnologySeries A$15.0M$542.3Msame sector · same stage
Viewpoint Molecular Targeting, Inc.BiotechnologySeries A$15.0M$427.6Msame sector · same stage
Meissa Vaccines IncBiotechnologySeries A$15.2M$503.1Msame sector · same stage
Zyomyx IncBiotechnologySeries A$15.2M$514.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
BioPhoundry, Inc.BiotechnologySeed$4.3M87%
Snap Bio, Inc.BiotechnologySeed$73.6M87%
Oral Genome Corp.BiotechnologySeed$11.2M86%
BioCurie, Inc.BiotechnologyPre-Seed$1.3M85%
SMSbiotech, Inc.BiotechnologySeries B$64.6M85%
OraLiva, Inc.BiotechnologySeed$5.1M85%
Mintech-Bio, Inc.BiotechnologyPre-Seed$7.2M85%
BioSurfaces, LLCBiotechnologyPre-Seed$49.7M85%
Frequently asked
How much funding has Bio-Dent, LTD. LLC raised?
Bio-Dent, LTD. LLC has raised approximately $15.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Bio-Dent, LTD. LLC's estimated valuation?
Provath's modeled valuation for Bio-Dent, LTD. LLC is approximately $542.3M (modeled range $16.4M–$2.9B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Bio-Dent, LTD. LLC at?
Bio-Dent, LTD. LLC's latest modeled financing stage is Series A. Its most recent recorded round closed around Sat Jul 01.
What does Bio-Dent, LTD. LLC do and where is it based?
Bio-Dent, LTD. LLC operates in the Biotechnology sector, based in SIMI VALLEY.
Explore related

See where Bio-Dent, LTD. LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Bio-Dent, LTD. LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.